Eurogentec Branch in Japan Receives ISO Certification for Production and Sales of IVD GMP Oligonucleotides
News Mar 04, 2010
Eurogentec S.A. has announced that Nippon EGT, a member of the Eurogentec group in Japan, recently received ISO13485:2003 certification for the production and sales of In Vitro Diagnostic (IVD) GMP-grade oligonucleotides.
ISO13485 is recognized as the global standard for quality management systems relating to the design, development, production, installation and servicing of medical devices.
“Nippon EGT supplies molecular diagnostics manufacturers and clinical testing laboratories with highly reliable and traceable IVD oligonucleotides which are controlled by the rigorous quality management system based on ISO13485,” said Dr. Yuko Yoneda, President of Nippon EGT. “Nippon EGT aims to be a leading supplier of IVD oligonucleotides in Japanese and Asian molecular diagnostics markets.”
“The Japanese ISO13485 certification completes yet another important milestone in Eurogentec’s strategy to further grow our presence in the global molecular diagnostics markets as a preferred supplier of IVD GMP assay components,” says Dr. Peter Haima, Eurogentec’s Director for Diagnostic Services.
“This rigorous medical device quality system certification provides added assurance to our clients in Asia that Eurogentec has established highly reliable, effective and reproducible processes for manufacturing of oligonucleotides used in molecular diagnostic devices and Lab Developed Tests (LDTs). In June this year we also plan to complete ISO13485 certification for our GMP/QSR compliant clean room oligo production facility in North America. With three fully harmonized ISO13485-certified facilities in Europe, North America and Japan we are able to offer our diagnostic clients uninterrupted supply of Diagnostic GMP oligos.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018